The WHO issues its first official guidance on GLP-1 drugs for obesity treatment, as the disease affects over one billion people globally and is expected to double by 2030.

Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid debate among health officials and doctors on how best to address anti-obesity and diabetes treatments,

Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and adolescents, according to a U.S. registry of clinical trials.

Recommending their long-term use, WHO also said people should undergo intensive behavioural therapy as part of a multi-pronged approach to treating obesity

Experts unpack the implications of CBER Director Vinay Prasad’s claim that COVID vaccines have caused 10+ child deaths; the 2025 Clinical Trials on Alzheimer’s Disease conference continues following two disappointing readouts;

Novo Nordisk submitted a higher-dose version of semaglutide (Wegovy) to the FDA for approval as a weight-management treatment. In STEP UP, adults with obesity lost an average 18.7% of their body weight with the 7.2-mg dose. State Medicaid officials are grappling with whether to cover pricey GLP-1 drugs for weight loss. ( Politico)

Bel, the French family-owned company, plans to invest €60 million in a second Babybel production line at its Sablé-sur-Sarthe factory in eastern France and is considering expanding its American facility.

The WHO issues its first official guidance on GLP-1 drugs for obesity treatment, as the disease affects over one billion people globally and is expected to double by 2030.